MedPath

Remimazolam

Generic Name
Remimazolam
Brand Names
Byfavo
Drug Type
Small Molecule
Chemical Formula
C21H19BrN4O2
CAS Number
308242-62-8
Unique Ingredient Identifier
7V4A8U16MB
Background

Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as inactive metabolites. These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed. Remimazolam was the first "soft" benzodiazepine analog to be developed and was approved for use by the FDA in July 2020 under the brand name Byfavo.

Indication

Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Associated Conditions
Procedural Sedation
Associated Therapies
-
Clinical Trials
Related News

Remimazolam vs Midazolam Cognitive and Motor Recovery After Intravenous Conscious Sedation for Dental Extractions.

Phase 3
Recruiting
Conditions
Tooth Extraction
Interventions
Drug: Remimazolam
Drug: Midazolam
First Posted Date
2022-02-02
Last Posted Date
2023-12-05
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
128
Registration Number
NCT05220462
Locations
🇬🇧

Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

The Comparison of Hypotension Incidence Between Remimazolam and Propofol in Hypertensive Patients Undergoing Neurosurgery

Not Applicable
Completed
Conditions
Patients Undergoing Neurosurgery
Interventions
Drug: propofol
Drug: remimazolam
First Posted Date
2021-12-20
Last Posted Date
2022-11-07
Lead Sponsor
Yonsei University
Target Recruit Count
100
Registration Number
NCT05164146
Locations
🇰🇷

Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam

Not Applicable
Recruiting
Conditions
Sedation and Analgesia
Interventions
Drug: Remimazolam
Drug: Midazolam
First Posted Date
2021-12-16
Last Posted Date
2023-07-14
Lead Sponsor
Zhujiang Hospital
Target Recruit Count
440
Registration Number
NCT05160987
Locations
🇨🇳

Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University, Guangzhou, Guangdong, China

The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

Not Applicable
Conditions
Anesthesia
Interventions
Drug: Remimazolam
First Posted Date
2021-09-22
Last Posted Date
2021-12-20
Lead Sponsor
Jianbo Yu
Target Recruit Count
120
Registration Number
NCT05053763
Locations
🇨🇳

Tianjin Nankai Hospital, Tianjin, Tianjin, China

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

Completed
Conditions
Myoma;Uterus
Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle
Polyp Endometrium
Interventions
Drug: Remimazolam
First Posted Date
2021-08-27
Last Posted Date
2022-04-25
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
38
Registration Number
NCT05025410
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Comparison of Postoperative QoR-15 Scores Between Desflurane and Remimazolam in Lumbar Fusion Surgery

Not Applicable
Completed
Conditions
Lumbar Fusion Surgery
Interventions
Drug: Desflurane
Drug: Remimazolam
First Posted Date
2021-07-30
Last Posted Date
2024-04-30
Lead Sponsor
Gangnam Severance Hospital
Target Recruit Count
76
Registration Number
NCT04983966
Locations
🇰🇷

GangnamSeverance Hospital, Seoul, Korea, Republic of

The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

Phase 4
Conditions
Anesthesia
Interventions
Drug: Remimazolam
First Posted Date
2021-07-20
Last Posted Date
2022-01-10
Lead Sponsor
Tianjin Nankai Hospital
Target Recruit Count
50
Registration Number
NCT04969068
Locations
🇨🇳

Tianjin Nankai Hospital, Tianjin, Tianjin, China

Remimazolam and Endovascular Procedures of Cerebrovascular Diseases

Not Applicable
Completed
Conditions
Cerebrovascular Disorders
Anesthesia
Interventions
Drug: remimazolam
Drug: propofol
First Posted Date
2021-07-06
Last Posted Date
2022-10-20
Lead Sponsor
Air Force Military Medical University, China
Target Recruit Count
142
Registration Number
NCT04950621
Locations
🇨🇳

Xijing hospital, Xi'an, Shaanxi, China

A Randomized Single-blind Clinical Trial of the Efficacy and Safety of Remimazolam in Painless Bronchoscopy

Phase 4
Conditions
Bronchoscopy
Sedation
Interventions
Drug: Remimazolam
Drug: Dexmedetomidine
First Posted Date
2021-06-09
Last Posted Date
2021-06-09
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
364
Registration Number
NCT04919174
Locations
🇨🇳

The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China

Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients

Phase 4
Completed
Conditions
Postoperative Nausea and Vomiting
High-risk Patients
Benzodiazepine
Interventions
Drug: Placebo
Drug: Remimazolam
First Posted Date
2021-04-27
Last Posted Date
2024-01-03
Lead Sponsor
Peking University First Hospital
Target Recruit Count
552
Registration Number
NCT04861337
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

🇨🇳

Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy